Property of Pepscan Systems BV
4of 4
Confidential
Patent and Publication
· JPM Langedijk
Title: Transport peptide among which C-terminal E
rns
peptide and analogs thereof
The patent is filed in United States of America, Australia, Canada, Europe,
Israel, Japan and New Zealand on December 30, 2002 and is a continuation of
International application PCT/NL01/00484. The application is published as
WO0200882 on January 3, 2002.
Priority date is June 28, 2000 (European patent appl. 00202255.6)
http://l2.espacenet.com/espacenet/viewer?PN=WO0200882&CY=nl&LG=nl&DB=EPD
· JPM Langedijk, Translocation activity of C-terminal domain of pestivirus Erns
and ribotoxin L3 loop, J Biol Chem. 2002 Feb 15;277(7):5308-14. (2001)
· JPM Langedijk, New transport peptides broaden the horizon of applications for
peptidic pharmaceuticals (in press)
In summary Pepscan Systems'XMTM can help solve intracellular delivery issues in
research and drug development because:
·
It can enhance transmembrane transport to obtain intracellular delivery of small
molecules, peptides, proteins and oligonucleotides.
·
It is only 16 amino acids long and best in class when comparing efficacy and
tolerability, mainly due to metabolic stabilization of the molecule
·
It is non-immunogenic
·
Customized linker design between drug and XMTM allows for maximum
flexibility for obtaining the desired delivery profile
·
The XMTM family of transport peptides and its potential applications are well
protected by a global IP portfolio
